An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Novartis Investigative Site, Berlin

Novartis Investigative Site, Berlin

Novartis Investigative Site, Kassel

Novartis Investigative Site, Essen

Novartis Investigative Site, Osnabrück

Novartis Investigative Site, Mainz

Novartis Investigative Site, Homburg

Novartis Investigative Site, München

Novartis Investigative Site, Erlangen

Novartis Investigative Site, Weiden

Novartis Investigative Site, Chemnitz